Mobile website
Clinical Research
Relationship between the expressions of HIF-1α and EGFR and the prognosis in patients with gastric carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To investigate the expression of hypoxia-inducible factor-1α (HIF-1α) and epithelial growth factor receptor (EGFR) and their relationship to clinicopathological features and prognosis of gastric cancer. Methods: 116 cases of gastric carcinoma tissues and 20 cases of tumor-adjacent tissues, resected from July 2008 to July 2010 in the First Affiliated Hospital of Nanyang Medical College, were analyzed for the expression of HIF-1α and EGFR by immnohistochemical staining, as well as their correlation with clinicopathological factors and survival time. Results:The positive rates of HIF-1α (63.8%) and EGFR (68.1%) in cancer tissues were significantly higher than those in tumor-adjacent tissues (P<0.01). The rate for both HIF-1α+ and EGFR+ was 50.9%. The expression of HIF-1α was correlated with T staging (P=0.014), and the co-expression of HIF-1α+ and EGFR+ was correlated with invasion depth and TNM stage (P=0.006 and P=0.023). Spearman rank correlation analysis illustrated that there was a significant positive correlation between HIF-1α and EGFR (r=0.331，P=0.000). Kaplan-Meier survival analysis showed that the survival time of patients with positive EGFR expression was significantly shorter than those with negative expression （29.6 months vs 48.4 months，P＜0.019）. The multivariate Cox regression analysis demonstrated that EGFR positivity, as an independent factor, could predict poor prognosis for patients with gastric cancer. Conclusion: HIF-1α and EGFR were highly expressed in the tissues of gastric cancer; HIF-1α and EGFR were closely related with each other, and may play important roles in development and progression of gastric carcinoma. EGFR positivity may be used as important index to evaluate the prognosis of gastric carcinoma.
Keywords:
Project Supported:
Project supported by the Foundation for Medical Science and Technology Program of Henan Province (No．201403213)
Clc Number:
